Reducing the risk of cardiovascular events in patients with type 2 diabetes, Noando ® was approved for new indications in China.

Specific contents of this approved indications include reducing the risk of major cardiovascular adverse events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adult patients with type 2 diabetes with cardiovascular disease.
so far, liraglutide injections will become the only sugar-lowering drug in China that currently has the risk of cardiovascular indications.
liraglutide is a glucagon-like peptide-1 (GLP-1) analogue in the country, approved by the FDA in 2010 for the treatment of adult type 2 diabetes, the product is called Victoza, 2017 was approved by the FDA for reducing the risk of heart attack, stroke and cardiovascular death in type 2 diabetes patients, and in June 2019, the FDA approved the extension of the treatment of diabetes.
2011, Liraglutide was approved in China, the product is called Nohe li®.
but because the price is too high, Nore's domestic sales situation is not optimistic.
July 2017, Noorpower successfully entered the health insurance catalog through negotiations, reducing the price of the 3ml:18mg specification to 410 yuan per serving.
into health insurance, Nordor has experienced significant volume sourm since the third quarter of 2017, with sales rising.
sales of Norda Power increased by 73% to DKK 521 million in 2018, accounting for 87% of the domestic GLP-1 market and 1.3% of the total diabetes market.
it is understood that the liraglutide compound patent expired in China in August 2017 and the crystal patent expired in 2022.
but according to the insight database, there are currently a number of domestic enterprises layout in this field, including Jianxiang Bio and Hanyu Pharmaceutical situ have submitted four types of generic drug listing applications, Chongqing PaiJin Bio and Zhengda Tianqing in THE BE test, Guangdong Dongsun, Tonghua Dongbao and Hangzhou Jiuyuan genetic engineering in the clinical phase of Phase III.
is expected to face more intense competition in the future with the approval of domestic liraglutide seine.
estimates that about 50% of deaths from type 2 diabetes worldwide are caused by cardiovascular disease.
this time liraglutide in China was officially approved to reduce the risk of cardiovascular events in type 2 diabetes, will undoubtedly further consolidate its position in the domestic diabetes market.
"-hearted diabetes: Cardiovascular risk to type 2 patients the main health threat type 2 diabetes is a complex metabolic disease characterized by high blood sugar, often accompanied by large vascular lesions (such as the heart, cerebrovascular and lower extremities), microvascular lesions (such as diabetic nephryne disease and diabetic retinopathy) and other complications. Among the
, cardiovascular disease is the main cause of disability and death in patients with type 2 diabetes.
globally, one diabetic has a heart attack every five minutes.
the risk of cardiovascular disease in diabetic patients increased by 2-4 times compared to non-diabetic people.
For diabetics, one of the purposes of sugar control is to reduce the risk of cardiovascular disease.
With more than 121 million diabetes cases in China, china has the highest number of diabetes cases, according to the International Diabetes Alliance (IDF). Among the
, the incidence of cardiovascular risk factors in type 2 diabetes patients was high, but the control rate was low.
, therefore, when developing treatment options for diabetics, we need to pay attention not only to blood sugar levels, but also to the patient's cardiovascular risk.
balance blood sugar with cardiovascular risk, move towards the "heart" era of diabetes management In the 2019 ESC/EASD Diabetes, Prediabetes Co-cardiovascular Disease Guidelines, GLP-1 receptor agonisant liraglutide is recommended for first-line treatment in patients with diabetes combined cardiovascular disease or with a high cardiovascular risk, noting that the cardiovascular benefits of GLP-1 receptor agonants are more likely to come from reduced atherosclerosis (ASCVD) events.
as one of the leading GLP-1 receptor agonists, Nora ® is currently the only GLP-1 analogue to be shown to reduce the risk of cardiovascular death. The cardiovascular benefits of
and ® come from their direct protective effects on the heart and blood vessels, which can continuously improve atherosclerosis.
a multi-country, multi-center long-term cardiovascular outcome trial, LED, has confirmed that noordal ® superior cardiovascular benefits significantly reduce the risk of major cardiovascular adverse events (MACE), including cardiovascular death, non-lethal myocardial infarction, or non-fatal stroke.
post-mortem analysis also suggests that Noorandor ® has a cardiovascular benefit mechanism independent of statin therapy.
results showed that for people with type 2 diabetes with cardiovascular disease, liraglutide significantly reduced the risk of MACE by 13%, significantly reduced the risk of total death by 15% and cardiovascular death by 22% on a standard treatment basis compared to placebo.
in the trial, the cardiovascular safety results of 92 Chinese subjects were generally consistent with the results of the trial sonofed by all subjects.
, Noorita ® can reduce the incidence of hypoglycemia while rapidly, efficiently and lastingly reducing the incidence of glycated hemoglobin (HbA1c) and better control a variety of cardiovascular risk factors, including blood pressure, lipids and weight.
this will effectively promote comprehensive disease management for people with type 2 diabetes and bring more benefits to patients. editor
: haon.